ADMINISTRATION The Office of Translational Research (OTR), under the leadership of CCSG deputy director Dr. Robert Bast, coordinates and implements all administrative functions related to the CCSG. Dr. Bast has a dual reporting relationship, reporting directly to Dr. Giulio Draetta, chief scientific officer, and to Dr. Peter Pisters, MD Anderson president and CCSG PI for matters relating to the CCSG. Dr. Bast's staff provides administrative support and financial, scientific, and technical oversight for the CCSG programs; for all institutional shared resources, including CCSG core facilities; and for all other CCSG components, including Clinical Protocol and Data Management (CPDM), the Protocol Review and Monitoring System (PRMS), Community Outreach and Engagement, Career Enhancement and Related Activities, Development Funds, Senior Leadership, Planning and Evaluation, and CCSG administrative supplements. OTR staff serve on many of MD Anderson's advisory and oversight committees, including MD Anderson's Moon Shot Operations and Executive Committee and committees responsible for capital equipment allocation, oversight of research data storage, and financial controls. Administrative support is provided in the following areas: 1) business operations and financial management of shared resources; 2) central organization and coordination for the scientific and technical aspects of shared resource operations; 3) facilitation of programmatic interactions and engagement; 4) facilitation of communication between center director, program leaders, shared resource directors, and program members; 5) development, management, and maintenance of databases for program funding, program membership, program member publications, program member biographical information, and shared resource utilization; 6) allocation and monitoring of the use of CCSG development funds; 7) coordination and writing of CCSG progress reports and competitive renewal applications; and 8) organization of CCSG Executive Committee and annual External Advisory Board meetings.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-44
Application #
9997791
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Lee, Chi Hyun; Ning, Jing; Shen, Yu (2018) Model diagnostics for the proportional hazards model with length-biased data. Lifetime Data Anal :
Cofta-Woerpel, Ludmila; Lam, Cho; Reitzel, Lorraine R et al. (2018) A tele-mentoring tobacco cessation case consultation and education model for healthcare providers in community mental health centers. Cogent Med 5:
Yeh, Jason C; Shank, Brandon R; Milton, DenĂ¡i R et al. (2018) Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis. Biol Blood Marrow Transplant 24:815-819
Dutcher, Giselle M A; Bilen, Mehmet Asim (2018) Therapeutic Vaccines for Genitourinary Malignancies. Vaccines (Basel) 6:
Kurnit, Katherine C; Dumbrava, Ecaterina E Ileana; Litzenburger, Beate et al. (2018) Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res 24:2719-2731
Duplisea, Jonathan J; Mokkapati, Sharada; Plote, Devin et al. (2018) The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World J Urol :
Jordan, V Craig (2018) Tamoxifen Resistance Trumped and Oral Selective Estrogen Receptor Degraders Arrive. Clin Cancer Res 24:3480-3482
Pantano, Naitielle; Hunt, Brady; Schwarz, Richard A et al. (2018) Is Proflavine Exposure Associated with Disease Progression in Women with Cervical Dysplasia? A Brief Report. Photochem Photobiol 94:1308-1313
Mehrvarz Sarshekeh, Amir; Xiong, Henry Q; Iizuka, Kenzo et al. (2018) Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer. Invest New Drugs 36:895-902
Lang, Frederick F; Conrad, Charles; Gomez-Manzano, Candelaria et al. (2018) Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. J Clin Oncol 36:1419-1427

Showing the most recent 10 out of 12418 publications